

William J Jusko

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9109115/publications.pdf>

Version: 2024-02-01

373
papers

15,808
citations

22548

61
h-index

36203

101
g-index

374
all docs

374
docs citations

374
times ranked

9324
citing authors

#	ARTICLE	IF	CITATIONS
1	Pharmacokinetic/pharmacodynamic modeling for dose selection for the first-in-human trial of the activated Factor XII inhibitor garadacimab (CSL312). <i>Clinical and Translational Science</i> , 2022, 15, 709-720.	1.5	7
2	Assessment of the Kochak-Benet Equation for Hepatic Clearance for the Parallel-Tube Model: Relevance of Classic Clearance Concepts in PK and PBPK. <i>AAPS Journal</i> , 2022, 24, 5.	2.2	16
3	PK/PD Assessment of Selective Phosphodiesterase Inhibitors in a Mouse Model of Autoimmune Hepatitis. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2022, , JPET-AR-2021-001004.	1.3	2
4	Consideration of Fractional Distribution Parameter f_d in the Chen and Gross Method for Tissue-to-Plasma Partition Coefficients: Comparison of Several Methods. <i>Pharmaceutical Research</i> , 2022, 39, 463-479.	1.7	9
5	Physiologically Based Pharmacokinetics of Lysosomotropic Chloroquine in Rat and Human. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2021, 376, 261-272.	1.3	12
6	Cross-species meta-analysis of dexamethasone pharmacokinetics utilizing allometric and scaling modeling approaches. <i>Biopharmaceutics and Drug Disposition</i> , 2021, 42, 191-203.	1.1	9
7	Pathway-level analysis of genome-wide circadian dynamics in diverse tissues in rat and mouse. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 2021, 48, 361-374.	0.8	3
8	Mathematical modeling of mammalian circadian clocks affecting drug and disease responses. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 2021, 48, 375-386.	0.8	7
9	Synergistic Pharmacodynamic Effects of Gemcitabine and Fibroblast Growth Factor Receptor Inhibitors on Pancreatic Cancer Cell Cycle Kinetics and Proliferation. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2021, 377, 370-384.	1.3	5
10	Population pharmacodynamic modeling of intramuscular and oral dexamethasone and betamethasone effects on six biomarkers with circadian complexities in Indian women. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 2021, 48, 411-438.	0.8	5
11	Meta-Assessment of Metformin Absorption and Disposition Pharmacokinetics in Nine Species. <i>Pharmaceuticals</i> , 2021, 14, 545.	1.7	13
12	Population pharmacokinetic modeling of intramuscular and oral dexamethasone and betamethasone in Indian women. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 2021, 48, 261-272.	0.8	9
13	Pharmacokinetics and Pharmacodynamics of Intramuscular and Oral Betamethasone and Dexamethasone in Reproductive Age Women in India. <i>Clinical and Translational Science</i> , 2020, 13, 391-399.	1.5	45
14	Seeking Nonspecific Binding: Assessing the Reliability of Tissue Dilutions for Calculating Fraction Unbound. <i>Drug Metabolism and Disposition</i> , 2020, 48, 894-902.	1.7	10
15	Modeling Pathway Dynamics of the Skeletal Muscle Response to Intravenous Methylprednisolone (MPL) Administration in Rats: Dosing and Tissue Effects. <i>Frontiers in Bioengineering and Biotechnology</i> , 2020, 8, 759.	2.0	2
16	Towards better combination regimens of cytarabine and FLT3 inhibitors in acute myeloid leukemia. <i>Cancer Chemotherapy and Pharmacology</i> , 2020, 86, 325-337.	1.1	4
17	Physiologically Based Pharmacokinetic Modeling Involving Nonlinear Plasma and Tissue Binding: Application to Prednisolone and Prednisone in Rats. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2020, 375, 385-396.	1.3	9
18	Exposure-Response Analysis of Vamorolone (VBP15) in Boys With Duchenne Muscular Dystrophy. <i>Journal of Clinical Pharmacology</i> , 2020, 60, 1385-1396.	1.0	8

#	ARTICLE	IF	CITATIONS
19	Pharmacokinetics of Hormonal Contraception in Individuals with Obesity: a Review. Current Obstetrics and Gynecology Reports, 2020, 9, 72-78.	0.3	3
20	Interactions of Tofacitinib and Dexamethasone on Lymphocyte Proliferation. Pharmaceutical Research, 2020, 37, 105.	1.7	3
21	Transitioning from Basic toward Systems Pharmacodynamic Models: Lessons from Corticosteroids. Pharmacological Reviews, 2020, 72, 414-438.	7.1	30
22	Physiologically Based Pharmacokinetics of Dexamethasone in Rats. Drug Metabolism and Disposition, 2020, 48, 811-818.	1.7	15
23	Pharmacokinetics of Inter-Alpha Inhibitor Proteins and Effects on Hemostasis After Hypoxic-Ischemic Brain Injury in Neonatal Rats. Current Pharmaceutical Design, 2020, 26, 3997-4006.	0.9	8
24	Modeling Combined Anti-Inflammatory Effects of Dexamethasone and Tofacitinib in Arthritic Rats. AAPS Journal, 2019, 21, 93.	2.2	5
25	Modeling Corticosteroid Pharmacokinetics and Pharmacodynamics, Part III: Estrous Cycle and Estrogen Receptor-Dependent Antagonism of Glucocorticoid-Induced Leucine Zipper (GILZ) Enhancement by Corticosteroids. Journal of Pharmacology and Experimental Therapeutics, 2019, 370, 337-349.	1.3	11
26	Journal editor's final report. Journal of Pharmacokinetics and Pharmacodynamics, 2019, 46, 511-512.	0.8	1
27	Indirect pharmacodynamic models for responses with circadian removal. Journal of Pharmacokinetics and Pharmacodynamics, 2019, 46, 89-101.	0.8	10
28	Modeling Corticosteroid Pharmacokinetics and Pharmacodynamics, Part I: Determination and Prediction of Dexamethasone and Methylprednisolone Tissue Binding in the Rat. Journal of Pharmacology and Experimental Therapeutics, 2019, 370, 318-326.	1.3	18
29	ATLAS mPBPK: A MATLAB-Based Tool for Modeling and Simulation of Minimal Physiologically-Based Pharmacokinetic Models. CPT: Pharmacometrics and Systems Pharmacology, 2019, 8, 557-566.	1.3	5
30	Modeling Corticosteroid Pharmacokinetics and Pharmacodynamics, Part II: Sex Differences in Methylprednisolone Pharmacokinetics and Corticosterone Suppression. Journal of Pharmacology and Experimental Therapeutics, 2019, 370, 327-336.	1.3	20
31	Pathway-Based Analysis of the Liver Response to Intravenous Methylprednisolone Administration in Rats: Acute Versus Chronic Dosing. Gene Regulation and Systems Biology, 2019, 13, 117762501984028.	2.3	6
32	Pharmacokinetics of the 1.5 mg levonorgestrel emergency contraceptive in women with normal, obese and extremely obese body mass index. Contraception, 2019, 99, 306-311.	0.8	15
33	Altered pharmacokinetics of combined oral contraceptives in obesity " multistudy assessment. Contraception, 2019, 99, 256-263.	0.8	14
34	Population Pharmacokinetics of Vamorolone (VBP15) in Healthy Men and Boys With Duchenne Muscular Dystrophy. Journal of Clinical Pharmacology, 2019, 59, 979-988.	1.0	11
35	Development and Translational Application of a Minimal Physiologically Based Pharmacokinetic Model for a Monoclonal Antibody against Interleukin 23 (IL-23) in IL-23-Induced Psoriasis-Like Mice. Journal of Pharmacology and Experimental Therapeutics, 2018, 365, 140-155.	1.3	19
36	Receptor/gene/protein-mediated signaling connects methylprednisolone exposure to metabolic and immune-related pharmacodynamic actions in liver. Journal of Pharmacokinetics and Pharmacodynamics, 2018, 45, 557-575.	0.8	7

#	ARTICLE	IF	CITATIONS
37	Pharmacogenomic Variability of Oral Baclofen Clearance and Clinical Response in Children With Cerebral Palsy. <i>PM and R</i> , 2018, 10, 235-243.	0.9	24
38	Daily variation of gene expression in diverse rat tissues. <i>PLoS ONE</i> , 2018, 13, e0197258.	1.1	32
39	Phase IIa trial in Duchenne muscular dystrophy shows vamorolone is a first-in-class dissociative steroidal anti-inflammatory drug. <i>Pharmacological Research</i> , 2018, 136, 140-150.	3.1	69
40	Modeling Sex Differences in Anti-inflammatory Effects of Dexamethasone in Arthritic Rats. <i>Pharmaceutical Research</i> , 2018, 35, 203.	1.7	21
41	Assessment of Three-Drug Combination Pharmacodynamic Interactions in Pancreatic Cancer Cells. <i>AAPS Journal</i> , 2018, 20, 80.	2.2	12
42	Physiologically-based pharmacokinetic and pharmacodynamic models for gemcitabine and birinapant in pancreatic cancer xenografts. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 2018, 45, 733-746.	0.8	8
43	Proteomic Analysis of Combined Gemcitabine and Birinapant in Pancreatic Cancer Cells. <i>Frontiers in Pharmacology</i> , 2018, 9, 84.	1.6	15
44	Role of Interstitial Fluid Turnover on Target Suppression by Therapeutic Biologics Using a Minimal Physiologically Based Pharmacokinetic Model. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2018, 367, 1-8.	1.3	16
45	Modeling circadian variability of core-clock and clock-controlled genes in four tissues of the rat. <i>PLoS ONE</i> , 2018, 13, e0197534.	1.1	13
46	Multi-Scale Network Model Supported by Proteomics for Analysis of Combined Gemcitabine and Birinapant Effects in Pancreatic Cancer Cells. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2018, 7, 549-561.	1.3	15
47	Modeling Corticosteroid Pharmacogenomics and Proteomics in Rat Liver. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2018, 367, 168-183.	1.3	10
48	Target-mediated drug disposition with drug-drug interaction, Part I: single drug case in alternative formulations. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 2017, 44, 17-26.	0.8	12
49	Target mediated drug disposition with drug-drug interaction, Part II: competitive and uncompetitive cases. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 2017, 44, 27-42.	0.8	12
50	Modeling Sex Differences in Pharmacokinetics, Pharmacodynamics, and Disease Progression Effects of Naproxen in Rats with Collagen-Induced Arthritis. <i>Drug Metabolism and Disposition</i> , 2017, 45, 484-491.	1.7	10
51	Effect of Disease-Related Changes in Plasma Albumin on the Pharmacokinetics of Naproxen in Male and Female Arthritic Rats. <i>Drug Metabolism and Disposition</i> , 2017, 45, 476-483.	1.7	5
52	Characterization and Interspecies Scaling of rhTNF- α Pharmacokinetics with Minimal Physiologically Based Pharmacokinetic Models. <i>Drug Metabolism and Disposition</i> , 2017, 45, 798-806.	1.7	11
53	Interrelationships between Infliximab and Recombinant Tumor Necrosis Factor- α in Plasma Using Minimal Physiologically Based Pharmacokinetic Models. <i>Drug Metabolism and Disposition</i> , 2017, 45, 790-797.	1.7	17
54	Modeling Combined Immunosuppressive and Anti-inflammatory Effects of Dexamethasone and Naproxen in Rats Predicts the Steroid-Sparing Potential of Naproxen. <i>Drug Metabolism and Disposition</i> , 2017, 45, 834-845.	1.7	23

#	ARTICLE	IF	CITATIONS
55	Functional proteomic analysis of corticosteroid pharmacodynamics in rat liver: Relationship to hepatic stress, signaling, energy regulation, and drug metabolism. <i>Journal of Proteomics</i> , 2017, 160, 84-105.	1.2	22
56	Mechanistic Multi-Tissue Modeling of Glucocorticoid-Induced Leucine Zipper Regulation: Integrating Circadian Gene Expression with Receptor-Mediated Corticosteroid Pharmacodynamics. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2017, 363, 45-57.	1.3	11
57	Effects of High-Fat Feeding on Skeletal Muscle Gene Expression in Diabetic Goto-Kakizaki Rats. <i>Gene Regulation and Systems Biology</i> , 2017, 11, 117762501771000.	2.3	4
58	Clarification of contraceptive drug pharmacokinetics in obesity. <i>Contraception</i> , 2017, 95, 10-16.	0.8	21
59	Perspectives on variability in pharmacokinetics of an oral contraceptive product. <i>Contraception</i> , 2017, 95, 5-9.	0.8	15
60	Understanding Physiology in the Continuum: Integration of Information from Multiple -Omics Levels. <i>Frontiers in Pharmacology</i> , 2017, 8, 91.	1.6	13
61	Pharmacodynamic Modeling of Cell Cycle Effects for Gemcitabine and Trabectedin Combinations in Pancreatic Cancer Cells. <i>Frontiers in Pharmacology</i> , 2016, 7, 421.	1.6	27
62	Foundations of Pharmacodynamic Systems Analysis. <i>AAPS Advances in the Pharmaceutical Sciences Series</i> , 2016, , 161-175.	0.2	4
63	Minimal physiologically-based pharmacokinetic (mPBPK) model for a monoclonal antibody against interleukin-6 in mice with collagen-induced arthritis. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 2016, 43, 291-304.	0.8	30
64	Assessment of non-linear combination effect terms for drug-drug interactions. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 2016, 43, 461-479.	0.8	27
65	Pharmacokinetics and bioequivalence of a liquid formulation of hydroxyurea in children with sickle cell anemia. <i>Journal of Clinical Pharmacology</i> , 2016, 56, 298-306.	1.0	14
66	Pharmacodynamic modeling of combined chemotherapeutic effects predicts synergistic activity of gemcitabine and trabectedin in pancreatic cancer cells. <i>Cancer Chemotherapy and Pharmacology</i> , 2016, 77, 181-193.	1.1	24
67	Quantitative tissue-specific dynamics of in vivo GILZ mRNA expression and regulation by endogenous and exogenous glucocorticoids. <i>Physiological Reports</i> , 2015, 3, e12382.	0.7	26
68	Modeling effects of dexamethasone on disease progression of bone mineral density in collagen-induced arthritic rats. <i>Pharmacology Research and Perspectives</i> , 2015, 3, e00169.	1.1	7
69	Effects of High Fat Feeding on Adipose Tissue Gene Expression in Diabetic Goto-Kakizaki Rats. <i>Gene Regulation and Systems Biology</i> , 2015, 9, GRSB.S25172.	2.3	14
70	Biodistribution of Etanercept to Tissues and Sites of Inflammation in Arthritic Rats. <i>Drug Metabolism and Disposition</i> , 2015, 43, 898-907.	1.7	16
71	Across-Species Scaling of Monoclonal Antibody Pharmacokinetics Using a Minimal PBPK Model. <i>Pharmaceutical Research</i> , 2015, 32, 3269-3281.	1.7	53
72	Tandem Analysis of Transcriptome and Proteome Changes after a Single Dose of Corticosteroid: A Systems Approach to Liver Function in Pharmacogenomics. <i>OMICS A Journal of Integrative Biology</i> , 2015, 19, 80-91.	1.0	18

#	ARTICLE	IF	CITATIONS
73	Mechanism-based population pharmacokinetic and pharmacodynamic modeling of intravenous and intranasal dexmedetomidine in healthy subjects. <i>European Journal of Clinical Pharmacology</i> , 2015, 71, 1197-1207.	0.8	42
74	Mechanism-based mathematical modeling of combined gemcitabine and birinapant in pancreatic cancer cells. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 2015, 42, 477-496.	0.8	27
75	Preface to the special issue to honor Gerhard Levy and 50 years of PK/PD. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 2015, 42, 427-427.	0.8	2
76	Perspectives on the history and scientific contributions of Gerhard Levy. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 2015, 42, 429-446.	0.8	6
77	Variability in Zucker diabetic fatty rats: differences in disease progression in hyperglycemic and normoglycemic animals. <i>Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy</i> , 2014, 7, 531.	1.1	12
78	Survey of monoclonal antibody disposition in man utilizing a minimal physiologically-based pharmacokinetic model. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 2014, 41, 571-580.	0.8	34
79	Tissue-Specific Gene Expression and Regulation in Liver and Muscle following Chronic Corticosteroid Administration. <i>Gene Regulation and Systems Biology</i> , 2014, 8, GRSB.S13134.	2.3	16
80	Highly Multiplexed and Reproducible Ion-Current-Based Strategy for Large-Scale Quantitative Proteomics and the Application to Protein Expression Dynamics Induced by Methylprednisolone in 60 Rats. <i>Analytical Chemistry</i> , 2014, 86, 8149-8157.	3.2	44
81	Incorporating target-mediated drug disposition in a minimal physiologically-based pharmacokinetic model for monoclonal antibodies. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 2014, 41, 375-387.	0.8	69
82	Population Pharmacokinetics of Oral Baclofen in Pediatric Patients with Cerebral Palsy. <i>Journal of Pediatrics</i> , 2014, 164, 1181-1188.e8.	0.9	29
83	Diabetes disease progression in Goto-Kakizaki rats: effects of salsalate treatment. <i>Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy</i> , 2014, 7, 381.	1.1	13
84	Interactions of Everolimus and Sorafenib in Whole Blood Lymphocyte Proliferation. <i>Pharmaceutical Research</i> , 2013, 30, 707-713.	1.7	2
85	Pharmacodynamic modeling of cell cycle and apoptotic effects of gemcitabine on pancreatic adenocarcinoma cells. <i>Cancer Chemotherapy and Pharmacology</i> , 2013, 72, 553-563.	1.1	49
86	Synergistic interactions between sorafenib and everolimus in pancreatic cancer xenografts in mice. <i>Cancer Chemotherapy and Pharmacology</i> , 2013, 71, 1231-1240.	1.1	29
87	Second-generation minimal physiologically-based pharmacokinetic model for monoclonal antibodies. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 2013, 40, 597-607.	0.8	123
88	Modeling pharmacokinetics/pharmacodynamics of abatacept and disease progression in collagen-induced arthritic rats: a population approach. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 2013, 40, 701-712.	0.8	13
89	Moving from Basic Toward Systems Pharmacodynamic Models. <i>Journal of Pharmaceutical Sciences</i> , 2013, 102, 2930-2940.	1.6	70
90	Evidence for a glucocorticoid receptor beta splice variant in the rat and its physiological regulation in liver. <i>Steroids</i> , 2013, 78, 312-320.	0.8	31

#	ARTICLE	IF	CITATIONS
91	Pharmacokinetics, pharmacodynamics and toxicities of methotrexate in healthy and collagen-induced arthritic rats. <i>Biopharmaceutics and Drug Disposition</i> , 2013, 34, 203-214.	1.1	22
92	Interactions of Everolimus and Sorafenib in Pancreatic Cancer Cells. <i>AAPS Journal</i> , 2013, 15, 78-84.	2.2	15
93	Study Reanalysis Using a Mechanism-Based Pharmacokinetic/Pharmacodynamic Model of Pramlintide in Subjects with Type 1 Diabetes. <i>AAPS Journal</i> , 2013, 15, 15-29.	2.2	10
94	Physiologically based pharmacokinetic models for everolimus and sorafenib in mice. <i>Cancer Chemotherapy and Pharmacology</i> , 2013, 71, 1219-1229.	1.1	26
95	Meta-Modeling of Methylprednisolone Effects on Glucose Regulation in Rats. <i>PLoS ONE</i> , 2013, 8, e81679.	1.1	11
96	Modeling Disease Progression and Rosiglitazone Intervention in Type 2 Diabetic Goto-Kakizaki Rats. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2012, 341, 617-625.	1.3	18
97	Effects of High Fat Feeding on Liver Gene Expression in Diabetic Goto-Kakizaki Rats. <i>Gene Regulation and Systems Biology</i> , 2012, 6, GRSB.S10371.	2.3	10
98	Target-Mediated Pharmacokinetic and Pharmacodynamic Model of Exendin-4 in Rats, Monkeys, and Humans. <i>Drug Metabolism and Disposition</i> , 2012, 40, 990-997.	1.7	34
99	Applications of minimal physiologically-based pharmacokinetic models. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 2012, 39, 711-723.	0.8	144
100	Use of Pharmacokinetic Data Below Lower Limit of Quantitation Values. <i>Pharmaceutical Research</i> , 2012, 29, 2628-2631.	1.7	22
101	Glucocorticoid Effects on Adiponectin Expression. <i>Vitamins and Hormones</i> , 2012, 90, 163-186.	0.7	33
102	Pharmacokinetic/Pharmacodynamic Modeling in Inflammation. <i>Critical Reviews in Biomedical Engineering</i> , 2012, 40, 295-312.	0.5	25
103	Pharmacokinetic/Pharmacodynamic Modeling of GLP-1 in Healthy Rats. <i>Pharmaceutical Research</i> , 2012, 29, 1078-1086.	1.7	21
104	Pharmacokinetic/Pharmacodynamic Modeling of Methylprednisolone Effects on iNOS mRNA Expression and Nitric Oxide During LPS-Induced Inflammation in Rats. <i>Pharmaceutical Research</i> , 2012, 29, 2060-2069.	1.7	16
105	Mechanism-based population pharmacokinetic modelling in diabetes: vildagliptin as a tight binding inhibitor and substrate of dipeptidyl peptidase IV. <i>British Journal of Clinical Pharmacology</i> , 2012, 73, 391-401.	1.1	29
106	Mechanism-based population modelling of the effects of vildagliptin on GLP-1, glucose and insulin in patients with type 2 diabetes. <i>British Journal of Clinical Pharmacology</i> , 2012, 73, 373-390.	1.1	19
107	Changes to journal of pharmacokinetics and pharmacodynamics. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 2012, 39, 1-1.	0.8	1
108	Differential muscle gene expression as a function of disease progression in Goto-Kakizaki diabetic rats. <i>Molecular and Cellular Endocrinology</i> , 2011, 338, 10-17.	1.6	42

#	ARTICLE	IF	CITATIONS
109	Mechanism-based disease progression modeling of type 2 diabetes in Goto-Kakizaki rats. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 2011, 38, 143-162.	0.8	22
110	Dynamic modeling of methylprednisolone effects on body weight and glucose regulation in rats. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 2011, 38, 293-316.	0.8	9
111	Mechanism-based population modelling for assessment of L-cell function based on total GLP-1 response following an oral glucose tolerance test. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 2011, 38, 713-725.	0.8	13
112	Population pharmacokinetic-pharmacodynamic disease progression model for effects of anakinra in Lewis rats with collagen-induced arthritis. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 2011, 38, 769-786.	0.8	20
113	Assessment of Pharmacologic Area Under the Curve When Baselines are Variable. <i>Pharmaceutical Research</i> , 2011, 28, 1081-1089.	1.7	62
114	Pharmacokinetic-Pharmacodynamic Disease Progression Model for Effect of Etanercept in Lewis Rats with Collagen-Induced Arthritis. <i>Pharmaceutical Research</i> , 2011, 28, 1622-1630.	1.7	34
115	Light-dark oscillations in the lung transcriptome: implications for lung homeostasis, repair, metabolism, disease, and drug action. <i>Journal of Applied Physiology</i> , 2011, 110, 1732-1747.	1.2	68
116	Mechanistic Modeling of the Effects of Glucocorticoids and Circadian Rhythms on Adipokine Expression. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2011, 337, 734-746.	1.3	27
117	Modeling Diabetes Disease Progression and Salsalate Intervention in Goto-Kakizaki Rats. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2011, 339, 896-904.	1.3	26
118	Pharmacokinetic and Pharmacodynamic Modeling of Exendin-4 in Type 2 Diabetic Goto-Kakizaki Rats. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2011, 336, 881-890.	1.3	35
119	Adipose Tissue Deficiency and Chronic Inflammation in Diabetic Goto-Kakizaki Rats. <i>PLoS ONE</i> , 2011, 6, e17386.	1.1	46
120	Circadian rhythms in gene expression: Relationship to physiology, disease, drug disposition and drug action. <i>Advanced Drug Delivery Reviews</i> , 2010, 62, 904-917.	6.6	110
121	New journal cover. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 2010, 37, 1-1.	0.8	1
122	Comparative analysis of acute and chronic corticosteroid pharmacogenomic effects in rat liver: Transcriptional dynamics and regulatory structures. <i>BMC Bioinformatics</i> , 2010, 11, 515.	1.2	18
123	Circadian signatures in rat liver: from gene expression to pathways. <i>BMC Bioinformatics</i> , 2010, 11, 540.	1.2	24
124	Pharmacokinetics and Pharmacodynamics of a Chimeric/Humanized Anti-CD3 Monoclonal Antibody, Otelixizumab (TRX4), in Subjects With Psoriasis and With Type 1 Diabetes Mellitus. <i>Journal of Clinical Pharmacology</i> , 2010, 50, 494-506.	1.0	34
125	Circadian variations in gene expression in rat abdominal adipose tissue and relationship to physiology. <i>Physiological Genomics</i> , 2010, 42A, 141-152.	1.0	44
126	Pharmacokinetic/Pharmacodynamic Modeling of Glucose Clamp Effects of Inhaled and Subcutaneous Insulin in Healthy Volunteers and Diabetic Patients. <i>Drug Metabolism and Pharmacokinetics</i> , 2010, 25, 418-429.	1.1	18

#	ARTICLE	IF	CITATIONS
127	Pharmacokinetic and Pharmacodynamic Modeling of a Copper-Selective Chelator (TETA) in Healthy Adults. <i>Journal of Clinical Pharmacology</i> , 2009, 49, 916-928.	1.0	25
128	Gene expression analysis of hepatic roles in cause and development of diabetes in Goto-Kakizaki rats. <i>Journal of Endocrinology</i> , 2009, 200, 331-346.	1.2	62
129	Mechanism-Based Modeling of Nutritional and Leptin Influences on Growth in Normal and Type 2 Diabetic Rats. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2009, 328, 644-651.	1.3	10
130	Pharmacodynamics of glucose regulation by methylprednisolone. II. normal rats. <i>Biopharmaceutics and Drug Disposition</i> , 2009, 30, 35-48.	1.1	16
131	Pharmacodynamics of glucose regulation by methylprednisolone. I. Adrenalectomized rats. <i>Biopharmaceutics and Drug Disposition</i> , 2009, 30, 21-34.	1.1	12
132	Quantitative Dynamic Models of Arthritis Progression in the Rat. <i>Pharmaceutical Research</i> , 2009, 26, 196-203.	1.7	27
133	Methods of utilizing baseline values for indirect response models. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 2009, 36, 381-405.	0.8	20
134	D-optimal designs for parameter estimation for indirect pharmacodynamic response models. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 2009, 36, 523-539.	0.8	8
135	Mechanistic population pharmacokinetics of total and unbound paclitaxel for a new nanodroplet formulation versus Taxol in cancer patients. <i>Cancer Chemotherapy and Pharmacology</i> , 2009, 63, 1049-1063.	1.1	43
136	Multiple-pool cell lifespan models for neutropenia to assess the population pharmacodynamics of unbound paclitaxel from two formulations in cancer patients. <i>Cancer Chemotherapy and Pharmacology</i> , 2009, 63, 1035-1048.	1.1	26
137	Scaling Pharmacodynamics from In Vitro and Preclinical Animal Studies to Humans. <i>Drug Metabolism and Pharmacokinetics</i> , 2009, 24, 16-24.	1.1	118
138	Modeling of Corticosteroid Effects on Hepatic Low-Density Lipoprotein Receptors and Plasma Lipid Dynamics in Rats. <i>Pharmaceutical Research</i> , 2008, 25, 769-780.	1.7	35
139	Pharmacodynamic model for chemotherapy-induced anemia in rats. <i>Cancer Chemotherapy and Pharmacology</i> , 2008, 62, 123-133.	1.1	41
140	Pharmacokinetic/Pharmacodynamic Modeling of Corticosterone Suppression and Lymphocytopenia by Methylprednisolone in Rats. <i>Journal of Pharmaceutical Sciences</i> , 2008, 97, 2820-2832.	1.6	31
141	Pharmacokinetics of dexamethasone in a rat model of rheumatoid arthritis. <i>Biopharmaceutics and Drug Disposition</i> , 2008, 29, 366-372.	1.1	26
142	Pharmacokinetic/Pharmacodynamic Modelling in Diabetes Mellitus. <i>Clinical Pharmacokinetics</i> , 2008, 47, 417-448.	1.6	83
143	Mathematical Modeling of Corticosteroid Pharmacogenomics in Rat Muscle following Acute and Chronic Methylprednisolone Dosing. <i>Molecular Pharmaceutics</i> , 2008, 5, 328-339.	2.3	24
144	Modeling Corticosteroid Effects in a Rat Model of Rheumatoid Arthritis I: Mechanistic Disease Progression Model for the Time Course of Collagen-Induced Arthritis in Lewis Rats. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2008, 326, 532-545.	1.3	65

#	ARTICLE	IF	CITATIONS
145	Circadian Variations in Rat Liver Gene Expression: Relationships to Drug Actions. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2008, 326, 700-716.	1.3	59
146	Modeling Corticosteroid Effects in a Rat Model of Rheumatoid Arthritis II: Mechanistic Pharmacodynamic Model for Dexamethasone Effects in Lewis Rats with Collagen-Induced Arthritis. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2008, 326, 546-554.	1.3	42
147	Relationships between circadian rhythms and modulation of gene expression by glucocorticoids in skeletal muscle. <i>American Journal of Physiology - Regulatory Integrative and Comparative Physiology</i> , 2008, 295, R1031-R1047.	0.9	64
148	Population Pharmacokinetics and Pharmacodynamics of Peptidic Erythropoiesis Receptor Agonist (ERA) in Healthy Volunteers. <i>Journal of Clinical Pharmacology</i> , 2008, 48, 43-52.	1.0	26
149	Pharmacodynamic Modeling of Acute and Chronic Effects of Methylprednisolone on Hepatic Urea Cycle Genes in Rats. <i>Gene Regulation and Systems Biology</i> , 2008, 2, 117762500800200.	2.3	5
150	Pharmacodynamic/Pharmacogenomic Modeling of Insulin Resistance Genes in Rat Muscle after Methylprednisolone Treatment: Exploring Regulatory Signaling Cascades. <i>Gene Regulation and Systems Biology</i> , 2008, 2, GRSB.S613.	2.3	3
151	Pharmacodynamic modeling of acute and chronic effects of methylprednisolone on hepatic urea cycle genes in rats. <i>Gene Regulation and Systems Biology</i> , 2008, 2, 1-19.	2.3	20
152	Interspecies Comparisons of Pharmacokinetics and Pharmacodynamics of Recombinant Human Erythropoietin. <i>Drug Metabolism and Disposition</i> , 2007, 35, 1672-1678.	1.7	70
153	Microarray analysis of the temporal response of skeletal muscle to methylprednisolone: comparative analysis of two dosing regimens. <i>Physiological Genomics</i> , 2007, 30, 282-299.	1.0	54
154	A Microarray Analysis of the Temporal Response of Liver to Methylprednisolone: A Comparative Analysis of Two Dosing Regimens. <i>Endocrinology</i> , 2007, 148, 2209-2225.	1.4	40
155	Pharmacokinetics of methylprednisolone after intravenous and intramuscular administration in rats. <i>Biopharmaceutics and Drug Disposition</i> , 2007, 28, 263-273.	1.1	30
156	Quantification of dexamethasone and corticosterone in rat biofluids and fetal tissue using highly sensitive analytical methods: assay validation and application to a pharmacokinetic study. <i>Biomedical Chromatography</i> , 2007, 21, 585-597.	0.8	32
157	Application of Scaling Factors in Simultaneous Modeling of Microarray Data from Diverse Chips. <i>Pharmaceutical Research</i> , 2007, 24, 643-649.	1.7	4
158	Population Pharmacokinetic/Pharmacodynamic Modeling of Systemic Corticosteroid Inhibition of Whole Blood Lymphocytes: Modeling Interoccasion Pharmacodynamic Variability. <i>Pharmaceutical Research</i> , 2007, 24, 1088-1097.	1.7	25
159	Assessing the Dynamics of Nuclear Glucocorticoid-Receptor Complex: Adding Flexibility to Gene Expression Modeling. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 2007, 34, 333-354.	0.8	13
160	Modeling receptor/gene-mediated effects of corticosteroids on hepatic tyrosine aminotransferase dynamics in rats: dual regulation by endogenous and exogenous corticosteroids. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 2007, 34, 643-667.	0.8	31
161	Target-mediated pharmacokinetic and pharmacodynamic model of recombinant human erythropoietin (rHuEPO). <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 2007, 34, 849-868.	0.8	63
162	Utility of Cleavable Isotope-Coded Affinity-Tagged Reagents for Quantification of Low-Copy Proteins Induced by Methylprednisolone Using Liquid Chromatography/Tandem Mass Spectrometry. <i>Analytical Chemistry</i> , 2006, 78, 4543-4552.	3.2	35

#	ARTICLE	IF	CITATIONS
163	Reduced Methylprednisolone Clearance Causing Prolonged Pharmacodynamics in a Healthy Subject Was Not Associated With CYP3A5*3 Allele or a Change in Diet Composition. <i>Journal of Clinical Pharmacology</i> , 2006, 46, 515-526.	1.0	10
164	Kinetics of Betamethasone and Fetal Cardiovascular Adverse Effects in Pregnant Sheep After Different Doses. <i>Obstetrics and Gynecology</i> , 2006, 108, 617-625.	1.2	19
165	Altered Methylprednisolone Pharmacodynamics in Healthy Subjects With Histamine N-Methyltransferase C314T Genetic Polymorphism. <i>Journal of Clinical Pharmacology</i> , 2006, 46, 408-417.	1.0	11
166	Modeling Circadian Rhythms of Glucocorticoid Receptor and Glutamine Synthetase Expression in Rat Skeletal Muscle. <i>Pharmaceutical Research</i> , 2006, 23, 670-679.	1.7	50
167	Assessment of Basic Indirect Pharmacodynamic Response Models with Physiological Limits. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 2006, 33, 167-193.	0.8	19
168	Pharmacodynamic Models for Agents that Alter Production of Natural Cells with Various Distributions of Lifespans. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 2006, 33, 125-166.	0.8	37
169	Assessment of Dosing Impact on Intra-Individual Variability in Estimation of Parameters for Basic Indirect Response Models. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 2006, 33, 635-655.	0.8	11
170	Modeling Glucocorticoid-Mediated Fetal Lung Maturation: I. Temporal Patterns of Corticosteroids in Rat Pregnancy. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2006, 317, 117-126.	1.3	26
171	Pharmacokinetic and Pharmacodynamic Modeling of Recombinant Human Erythropoietin after Intravenous and Subcutaneous Administration in Rats. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2006, 319, 1297-1306.	1.3	64
172	Modeling Glucocorticoid-Mediated Fetal Lung Maturation: II. Temporal Patterns of Gene Expression in Fetal Rat Lung. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2006, 317, 127-138.	1.3	17
173	Physiologically Based Pharmacokinetic Modeling of FTY720 (2-Amino-2-[2-(4-octylphenyl)ethyl]propane-1,3-diol hydrochloride) in Rats After Oral and Intravenous Doses. <i>Drug Metabolism and Disposition</i> , 2006, 34, 1480-1487.	1.7	125
174	Stability of dexamethasone sodium phosphate in rat plasma. <i>International Journal of Pharmaceutics</i> , 2005, 301, 262-266.	2.6	31
175	Semi-mechanistic pharmacokinetic/pharmacodynamic modelling of the antimalarial effect of artemisinin. <i>British Journal of Clinical Pharmacology</i> , 2005, 60, 594-604.	1.1	38
176	Pharmacokinetic and pharmacodynamic modeling of recombinant human erythropoietin after multiple subcutaneous doses in healthy subjects. <i>European Journal of Pharmaceutical Sciences</i> , 2005, 26, 295-306.	1.9	90
177	Comparison of dexamethasone pharmacokinetics in female rats after intravenous and intramuscular administration. <i>Biopharmaceutics and Drug Disposition</i> , 2005, 26, 85-91.	1.1	48
178	Pharmacodynamic interactions between recombinant mouse interleukin-10 and prednisolone using a mouse endotoxemia model. <i>Journal of Pharmaceutical Sciences</i> , 2005, 94, 590-603.	1.6	20
179	Population Cell Life Span Models for Effects of Drugs Following Indirect Mechanisms of Action. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 2005, 32, 767-793.	0.8	41
180	Pharmacokinetics and Pharmacodynamics of PEGylated IFN- γ 1a Following Subcutaneous Administration in Monkeys. <i>Pharmaceutical Research</i> , 2005, 22, 58-61.	1.7	39

#	ARTICLE	IF	CITATIONS
181	Corticosteroid-regulated genes in rat kidney: mining time series array data. American Journal of Physiology - Endocrinology and Metabolism, 2005, 289, E870-E882.	1.8	43
182	Temporal profiling of the transcriptional basis for the development of corticosteroid-induced insulin resistance in rat muscle. Journal of Endocrinology, 2005, 184, 219-232.	1.2	59
183	BETAMETHASONE PHARMACOKINETICS AFTER TWO PRODRUG FORMULATIONS IN SHEEP: IMPLICATIONS FOR ANTENATAL CORTICOSTEROID USE. Drug Metabolism and Disposition, 2005, 33, 1124-1130.	1.7	50
184	Pharmacogenomic responses of rat liver to methylprednisolone: An approach to mining a rich microarray time series. AAPS Journal, 2005, 7, E156-E194.	2.2	37
185	Receptor/Gene-Mediated Pharmacodynamic Effects of Methylprednisolone on Phosphoenolpyruvate Carboxykinase Regulation in Rat Liver. Journal of Pharmacology and Experimental Therapeutics, 2004, 309, 328-339.	1.3	47
186	The genomic response of skeletal muscle to methylprednisolone using microarrays: tailoring data mining to the structure of the pharmacogenomic time series. Pharmacogenomics, 2004, 5, 525-552.	0.6	27
187	Assessment of Drug Interactions Relevant to Pharmacodynamic Indirect Response Models. Journal of Pharmacokinetics and Pharmacodynamics, 2004, 31, 345-380.	0.8	41
188	Area/Moment and Compartmental Modeling of Pharmacokinetics During Pregnancy: Applications to Maternal/Fetal Exposures to Corticosteroids in Sheep and Rats. Pharmaceutical Research, 2004, 21, 2279-2292.	1.7	18
189	Stabilization and HPLC Analysis of Betamethasone Sodium Phosphate in Plasma. Journal of Pharmaceutical Sciences, 2004, 93, 726-732.	1.6	20
190	Modeling the metabolic effects of terbutaline in β 2-adrenergic receptor diplotypes*1. Clinical Pharmacology and Therapeutics, 2004, 76, 27-37.	2.3	33
191	Pharmacokinetic and Pharmacodynamic Modeling of Recombinant Human Erythropoietin After Single and Multiple Doses in Healthy Volunteers. Journal of Clinical Pharmacology, 2004, 44, 991-1002.	1.0	122
192	Interactions of Prednisolone and Other Immunosuppressants Used in Dual Treatment of Systemic Lupus Erythematosus in Lymphocyte Proliferation Assays. Journal of Clinical Pharmacology, 2004, 44, 1034-1045.	1.0	9
193	Gene arrays and temporal patterns of drug response: corticosteroid effects on rat liver. Functional and Integrative Genomics, 2003, 3, 171-179.	1.4	27
194	Integrated QSPR \rightarrow Pharmacodynamic Model of Genomic Effects of Several Corticosteroids. Journal of Pharmaceutical Sciences, 2003, 92, 881-889.	1.6	17
195	Comparative pharmacokinetics of coumarin anticoagulants L: Physiologic modeling of S-warfarin in rats and pharmacologic target-mediated warfarin disposition in man. Journal of Pharmaceutical Sciences, 2003, 92, 985-994.	1.6	54
196	Relative immunosuppressive potency of therapeutic corticosteroids measured by whole blood lymphocyte proliferation. Journal of Pharmaceutical Sciences, 2003, 92, 1521-1525.	1.6	41
197	Pharmacokinetic and Pharmacodynamic Modeling of Recombinant Human Erythropoietin after Intravenous and Subcutaneous Dose Administration in Cynomolgus Monkeys. Journal of Pharmacology and Experimental Therapeutics, 2003, 306, 324-331.	1.3	59
198	Receptor-Mediated Pharmacokinetics and Pharmacodynamics of Interferon- β 1a in Monkeys. Journal of Pharmacology and Experimental Therapeutics, 2003, 306, 262-270.	1.3	76

#	ARTICLE	IF	CITATIONS
199	Modeling of Corticosteroid Pharmacogenomics in Rat Liver Using Gene Microarrays. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2003, 307, 93-109.	1.3	135
200	In vivo multi-tissue corticosteroid microarray time series available online at Public Expression Profile Resource (PEPR). <i>Pharmacogenomics</i> , 2003, 4, 791-799.	0.6	24
201	Dose Equivalency Evaluation of Major Corticosteroids: Pharmacokinetics and Cell Trafficking and Cortisol Dynamics. <i>Journal of Clinical Pharmacology</i> , 2003, 43, 1216-1227.	1.0	132
202	Diversity of Mechanism-Based Pharmacodynamic Models. <i>Drug Metabolism and Disposition</i> , 2003, 31, 510-518.	1.7	318
203	Pharmacodynamics and Pharmacogenomics of Methylprednisolone during 7-Day Infusions in Rats. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2002, 300, 245-256.	1.3	52
204	Pharmacodynamic Modeling of Thrombopoietin, Platelet, and Megakaryocyte Dynamics in Patients with Acute Myeloid Leukemia Undergoing Dose Intensive Chemotherapy. <i>Journal of Clinical Pharmacology</i> , 2002, 42, 501-511.	1.0	10
205	Quantitative Structure-Pharmacokinetic/Pharmacodynamic Relationships of Corticosteroids in Man. <i>Journal of Pharmaceutical Sciences</i> , 2002, 91, 2441-2451.	1.6	39
206	Pharmacodynamic Interaction of Recombinant Human Interleukin-10 and Prednisolone Using in vitro Whole Blood Lymphocyte Proliferation. <i>Journal of Pharmaceutical Sciences</i> , 2002, 91, 1334-1342.	1.6	50
207	Pharmacokinetic/pharmacodynamic model for prednisolone inhibition of whole blood lymphocyte proliferation. <i>British Journal of Clinical Pharmacology</i> , 2002, 53, 474-484.	1.1	43
208	Fifth-generation model for corticosteroid pharmacodynamics: application to steady-state receptor down-regulation and enzyme induction patterns during seven-day continuous infusion of methylprednisolone in rats. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 2002, 29, 1-24.	0.8	111
209	Pharmacodynamics and pharmacogenomics of diverse receptor-mediated effects of methylprednisolone in rats using microarray analysis. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 2002, 29, 103-129.	0.8	30
210	Receptor-mediated pharmacokinetic/pharmacodynamic model of interferon-beta 1a in humans. <i>Pharmaceutical Research</i> , 2002, 19, 1537-1543.	1.7	55
211	Multiple-pool cell lifespan model of hematologic effects of anticancer agents. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 2002, 29, 311-337.	0.8	32
212	Pharmacokinetic and pharmacodynamic interactions between diltiazem and methylprednisolone in healthy volunteers. <i>Clinical Pharmacology and Therapeutics</i> , 2002, 72, 370-382.	2.3	27
213	Prednisolone Pharmacokinetics and Pharmacodynamics in Relation to Sex and Race. <i>Journal of Clinical Pharmacology</i> , 2001, 41, 1180-1194.	1.0	93
214	Interactions of aspirin and salicylic acid with prednisolone for inhibition of lymphocyte proliferation. <i>International Immunopharmacology</i> , 2001, 1, 2035-2042.	1.7	16
215	Pharmacodynamic Modeling of Lansoprazole Using an Indirect Irreversible Response Model. <i>Journal of Clinical Pharmacology</i> , 2001, 41, 251-258.	1.0	24
216	General pharmacokinetic model for drugs exhibiting target-mediated drug disposition. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 2001, 28, 507-532.	0.8	501

#	ARTICLE	IF	CITATIONS
217	Indirect pharmacodynamic models for responses with multicompartamental distribution or polyexponential disposition. , 2001, 28, 57-78.		21
218	Pharmacodynamic modeling of time-dependent transduction systems. <i>Clinical Pharmacology and Therapeutics</i> , 2001, 70, 210-216.	2.3	125
219	Role of dosage regimen in controlling indirect pharmacodynamic responses1PII of the original article: S0169-409X(98)â€”30-1. The article was originally published in <i>Advanced Drug Delivery Reviews</i> 33 (1998) 221â€”233.1. <i>Advanced Drug Delivery Reviews</i> , 2001, 46, 45-57.	6.6	11
220	Effects of Oral Prasterone (Dehydroepiandrosterone) on Single-Dose Pharmacokinetics of Oral Prednisone and Cortisol Suppression in Normal Women. <i>Journal of Clinical Pharmacology</i> , 2001, 41, 1195-1205.	1.0	19
221	Modeling of dose-response-time data: four examples of estimating the turnover parameters and generating kinetic functions from response profiles. <i>Biopharmaceutics and Drug Disposition</i> , 2000, 21, 41-52.	1.1	54
222	Developing compliance instructions for drug labeling. <i>Clinical Pharmacology and Therapeutics</i> , 2000, 68, 586-591.	2.3	32
223	ALGORITHM FOR APPLICATION OF FOURIER ANALYSIS FOR BIORHYTHMIC BASELINES OF PHARMACODYNAMIC INDIRECT RESPONSE MODELS. <i>Chronobiology International</i> , 2000, 17, 77-93.	0.9	40
224	Pharmacokinetics and Pharmacodynamics of Avitriptan during Intravenous Administration in Healthy Subjects. <i>Journal of Clinical Pharmacology</i> , 1999, 39, 685-694.	1.0	3
225	Influence of Gender on Prednisolone Effects on Whole Blood T-Cell Deactivation and Trafficking in Rats. <i>Journal of Pharmaceutical Sciences</i> , 1999, 88, 46-51.	1.6	7
226	Role of baseline parameters in determining indirect pharmacodynamic responses. <i>Journal of Pharmaceutical Sciences</i> , 1999, 88, 987-990.	1.6	19
227	Pharmacodynamic interactions of interleukin-10 and prednisone in healthy volunteers. <i>Clinical Pharmacology and Therapeutics</i> , 1999, 65, 304-318.	2.3	27
228	Pharmacokinetic-pharmacodynamic modeling of ipamorelin, a growth hormone releasing peptide, in human volunteers. <i>Pharmaceutical Research</i> , 1999, 16, 1412-1416.	1.7	26
229	Mathematical modeling of circadian cortisol concentrations using indirect response models: comparison of several methods. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 1999, 27, 23-43.	0.6	78
230	Modeling interactions between adrenal suppression and T-helper lymphocyte trafficking during multiple dosing of methylprednisolone. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 1999, 27, 559-575.	0.6	22
231	Accumulation of Antibody-Target Complexes and the Pharmacodynamics of Clotting after Single Intravenous Administration of Humanized Anti-Factor IX Monoclonal Antibody to Rats. <i>Drug Delivery</i> , 1999, 6, 171-179.	2.5	7
232	Basic pharmacodynamic models for agents that alter production of natural cells. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 1999, 27, 467-489.	0.8	76
233	Immunodynamics of methylprednisolone induced T-cell trafficking and deactivation using whole blood lymphocyte proliferation techniques in the rat. , 1999, 20, 255-261.		3
234	Pharmacokinetics and Pharmacodynamics of Cumulative Single Doses of Inhaled Salbutamol Enantiomers in Asthmatic Subjects. <i>Pulmonary Pharmacology and Therapeutics</i> , 1999, 12, 353-362.	1.1	57

#	ARTICLE	IF	CITATIONS
235	Pharmacokinetic and Adrenal Interactions of IL-10 and Prednisone in Healthy Volunteers. Journal of Clinical Pharmacology, 1999, 39, 624-635.	1.0	27
236	Pharmacokinetics and leukocyte responses of recombinant human interleukin-10. Pharmaceutical Research, 1998, 15, 1895-1901.	1.7	63
237	Note: caution in use of empirical equations for pharmacodynamic indirect response models. Journal of Pharmacokinetics and Pharmacodynamics, 1998, 26, 735-741.	0.6	3
238	Dose-dependence and repeated-dose studies for receptor/gene-mediated pharmacodynamics of methylprednisolone on glucocorticoid receptor down-regulation and tyrosine aminotransferase induction in rat liver. Journal of Pharmacokinetics and Pharmacodynamics, 1998, 26, 619-648.	0.6	46
239	Mathematical formalism and characteristics of four basic models of indirect pharmacodynamic responses for drug infusions. Journal of Pharmacokinetics and Pharmacodynamics, 1998, 26, 385-408.	0.6	26
240	Fourth-generation model for corticosteroid pharmacodynamics: a model for methylprednisolone effects on receptor/gene-mediated glucocorticoid receptor down-regulation and tyrosine aminotransferase induction in rat liver. Journal of Pharmacokinetics and Pharmacodynamics, 1998, 26, 289-317.	0.8	63
241	Pharmacokinetic-pharmacodynamic modeling of tolmetin antinociceptive effect in the rat using an indirect response model: a population approach. Journal of Pharmacokinetics and Pharmacodynamics, 1998, 26, 547-557.	0.8	22
242	Integrated Functions for Four Basic Models of Indirect Pharmacodynamic Response. Journal of Pharmaceutical Sciences, 1998, 87, 67-72.	1.6	46
243	Transit Compartments versus Gamma Distribution Function To Model Signal Transduction Processes in Pharmacodynamics. Journal of Pharmaceutical Sciences, 1998, 87, 732-737.	1.6	138
244	Precursor-dependent indirect pharmacodynamic response model for tolerance and rebound phenomena—Supported in part by Grant No. 24211 from the National Institute of General Medical Science, National Institutes of Health.. Journal of Pharmaceutical Sciences, 1998, 87, 1577-1584.	1.6	115
245	Characteristics of indirect pharmacodynamic models and applications to clinical drug responses. British Journal of Clinical Pharmacology, 1998, 45, 229-239.	1.1	178
246	GENDER-RELATED ASSESSMENT OF CYCLOSPORINE/PREDNISOLONE/SIROLIMUS INTERACTIONS IN THREE HUMAN LYMPHOCYTE PROLIFERATION ASSAYS ¹ . Transplantation, 1998, 65, 1203-1209.	0.5	26
247	Mathematical formalism for the properties of four basic models of indirect pharmacodynamic responses. Journal of Pharmacokinetics and Pharmacodynamics, 1997, 25, 107-123.	0.6	55
248	Application of moment analysis to the sigmoid effect model for drug administered intravenously. , 1997, 14, 949-952.		8
249	Nonlinear perpendicular least-squares regression in pharmacodynamics. , 1997, 18, 711-716.		5
250	Corticosteroid effects in skeletal muscle: Gene induction/receptor autoregulation. , 1997, 20, 1318-1320.		21
251	Population pharmacokinetics of sirolimus in kidney transplant patients*. Clinical Pharmacology and Therapeutics, 1997, 61, 416-428.	2.3	100
252	Synergistic Interaction Between Dehydroepiandrosterone and Prednisolone in the Inhibition of Rat Lymphocyte Proliferation. Immunopharmacology and Immunotoxicology, 1996, 18, 443-456.	1.1	11

#	ARTICLE	IF	CITATIONS
253	Pharmacokinetics of Prednisolone During Administration of Sirolimus in Patients with Renal Transplants. <i>Journal of Clinical Pharmacology</i> , 1996, 36, 1100-1106.	1.0	46
254	Characterization of four basic models of indirect pharmacodynamic responses. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 1996, 24, 611-635.	0.6	113
255	Liposomal methylprednisolone in rats: dose-proportionality and chronic-dose pharmacokinetics/pharmacodynamics. <i>Pharmaceutical Research</i> , 1996, 13, 141-145.	1.7	8
256	Oral contraceptive effects on methylprednisolone pharmacokinetics and pharmacodynamics*. <i>Clinical Pharmacology and Therapeutics</i> , 1996, 59, 312-321.	2.3	50
257	Pharmacokinetics of tacrolimus in liver transplant patients*. <i>Clinical Pharmacology and Therapeutics</i> , 1995, 57, 281-290.	2.3	216
258	Tolrestat pharmacokinetic and pharmacodynamic effects on red blood cell sorbitol levels in normal volunteers and in patients with insulin-dependent diabetes*. <i>Clinical Pharmacology and Therapeutics</i> , 1995, 58, 631-640.	2.3	17
259	Pharmacokinetics and receptor-mediated pharmacodynamics of corticosteroids. <i>Toxicology</i> , 1995, 102, 189-196.	2.0	43
260	Convergence of direct and indirect pharmacodynamic response models. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 1995, 23, 5-8.	0.6	54
261	Third-generation model for corticosteroid pharmacodynamics: Roles of glucocorticoid receptor mRNA and tyrosine aminotransferase mRNA in rat liver. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 1995, 23, 163-181.	0.6	32
262	Effect of corticosteroid binding globulin on the pharmacokinetics of prednisolone in rats. <i>Pharmaceutical Research</i> , 1995, 12, 902-904.	1.7	9
263	Pharmacodynamic modeling of prednisolone effects on natural killer cell trafficking. <i>Pharmaceutical Research</i> , 1995, 12, 459-463.	1.7	6
264	Combined Inhibition Effects of Tacrolimus and Methylprednisolone on in Vitro Human Lymphocyte Proliferation. <i>Immunopharmacology and Immunotoxicology</i> , 1995, 17, 335-345.	1.1	8
265	Differential dynamics of receptor down-regulation and tyrosine aminotransferase induction following glucocorticoid treatment. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 1995, 54, 237-243.	1.2	34
266	Inhibition of Phytohaemagglutinin-Induced Lymphocyte Proliferation by Immunosuppressive Drugs: Use of Whole Blood Culture. <i>Immunopharmacology and Immunotoxicology</i> , 1994, 16, 389-401.	1.1	25
267	Bioavailability and reversible metabolism of prednisone and prednisolone in man. <i>Biopharmaceutics and Drug Disposition</i> , 1994, 15, 163-172.	1.1	59
268	An algorithm and computer program for calculating the mean transit time and distribution rate parameters of generated metabolites undergoing linear tissue distribution and linear or non-linear central elimination. <i>Biopharmaceutics and Drug Disposition</i> , 1994, 15, 273-294.	1.1	3
269	Mean residence time concepts for non-linear pharmacokinetic systems. <i>Biopharmaceutics and Drug Disposition</i> , 1994, 15, 627-641.	1.1	13
270	Fifteen years of operation of a high-performance liquid chromatographic assay for prednisolone, cortisol and prednisone in plasma. <i>Biomedical Applications</i> , 1994, 658, 47-54.	1.7	54

#	ARTICLE	IF	CITATIONS
271	Inhibition of rat splenocyte proliferation with methylprednisolone: in vivo effect of liposomal formulation. <i>Pharmaceutical Research</i> , 1994, 11, 848-854.	1.7	20
272	Effects of acute and chronic inflammation on the pharmacokinetics of prednisolone in rats. <i>Pharmaceutical Research</i> , 1994, 11, 541-544.	1.7	5
273	Pharmacodynamic model for joint exogenous and endogenous corticosteroid suppression of lymphocyte trafficking. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 1994, 22, 469-480.	0.6	36
274	Pharmacodynamic modeling of nonsteroidal anti-inflammatory drugs: antipyretic effect of ibuprofen. <i>Clinical Pharmacology and Therapeutics</i> , 1994, 55, 87-88.	2.3	20
275	Prednisolone pharmacodynamics: Leukocyte trafficking in the rat. <i>Life Sciences</i> , 1994, 55, PL371-PL378.	2.0	11
276	Physiologic indirect response models characterize diverse types of pharmacodynamic effects. <i>Clinical Pharmacology and Therapeutics</i> , 1994, 56, 406-419.	2.3	322
277	THE PHARMACOKINETICS AND PHARMACODYNAMICS OF METHYLPREDNISOLONE IN CHRONIC RENAL FAILURE. <i>American Journal of Therapeutics</i> , 1994, 1, 49-57.	0.5	12
278	Pharmacokinetics of reversible metabolic systems. <i>Biopharmaceutics and Drug Disposition</i> , 1993, 14, 721-766.	1.1	37
279	Conceptualization of drug distribution to a hypothetical pharmacodynamic effect compartment. <i>Clinical Pharmacology and Therapeutics</i> , 1993, 54, 112-113.	2.3	8
280	Gender-based effects on methylprednisolone pharmacokinetics and pharmacodynamics. <i>Clinical Pharmacology and Therapeutics</i> , 1993, 54, 402-414.	2.3	164
281	Mean residence time of oral drugs undergoing first-pass and linear reversible metabolism. <i>Pharmaceutical Research</i> , 1993, 10, 8-13.	1.7	13
282	Enhancement of tissue delivery and receptor occupancy of methylprednisolone in rats by a liposomal formulation. <i>Pharmaceutical Research</i> , 1993, 10, 1402-1410.	1.7	20
283	Comparison of four basic models of indirect pharmacodynamic responses. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 1993, 21, 457-478.	0.6	699
284	Pharmacokinetic Principles of Drug Distribution in Saliva. <i>Annals of the New York Academy of Sciences</i> , 1993, 694, 36-47.	1.8	78
285	Pharmacokinetics of Methylprednisolone Hemisuccinate and Methylprednisolone in Chronic Liver Disease. <i>Journal of Clinical Pharmacology</i> , 1993, 33, 805-810.	1.0	8
286	Pharmacokinetics and pharmacodynamics of methylprednisolone when administered at 8 AM versus 4 PM. <i>Clinical Pharmacology and Therapeutics</i> , 1992, 51, 677-688.	2.3	40
287	Effect of the Anti-inflammatory Agent Tenidap on the Pharmacokinetics and Pharmacodynamics of Prednisolone. <i>Journal of Clinical Pharmacology</i> , 1992, 32, 222-230.	1.0	12
288	Receptor-mediated methylprednisolone pharmacodynamics in rats: Steroid-induced receptor down-regulation. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 1992, 20, 333-355.	0.6	15

#	ARTICLE	IF	CITATIONS
289	Pharmacokinetics and pharmacodynamics of methylprednisolone: Trafficking of helper T lymphocytes. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 1992, 20, 319-331.	0.6	41
290	Evaluation of dose-related pharmacokinetics and pharmacodynamics of prednisolone in man. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 1992, 20, 567-589.	0.6	62
291	Corticosteroid pharmacodynamic modeling: osteocalcin suppression by prednisolone. <i>Pharmaceutical Research</i> , 1992, 09, 1096-1098.	1.7	11
292	Bioavailability and Nonlinear Disposition of Methylprednisolone and Methylprednisone in the Rat. <i>Journal of Pharmaceutical Sciences</i> , 1992, 81, 117-121.	1.6	21
293	Mean residence times and distribution volumes for drugs undergoing linear reversible metabolism and tissue distribution and linear or nonlinear elimination from the central compartments. <i>Pharmaceutical Research</i> , 1991, 08, 508-511.	1.7	16
294	Two-compartment basophil cell trafficking model for methylprednisolone pharmacodynamics. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 1991, 19, 521-536.	0.6	39
295	Pharmacokinetics and pharmacodynamics of methylprednisolone in obesity. <i>Clinical Pharmacology and Therapeutics</i> , 1991, 49, 536-549.	2.3	61
296	Lack of pharmacokinetic and pharmacodynamic interactions between ketoconazole and prednisolone. <i>Clinical Pharmacology and Therapeutics</i> , 1991, 49, 558-570.	2.3	36
297	Drug redistribution and mean transit time concepts for nonlinear pharmacokinetic systems. <i>Biopharmaceutics and Drug Disposition</i> , 1991, 12, 73-79.	1.1	3
298	Disposition of Methylprednisolone and Its Sodium Succinate Prodrug In Vivo and in Perfused Liver of Rats: Nonlinear and Sequential First-Pass Elimination. <i>Journal of Pharmaceutical Sciences</i> , 1991, 80, 409-415.	1.6	32
299	Ketoconazole effects on corticosteroid disposition. <i>Clinical Pharmacology and Therapeutics</i> , 1990, 47, 418-419.	2.3	1
300	Nonlinear pharmacokinetics and interconversion of prednisolone and prednisone in rats. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 1990, 18, 401-421.	0.6	18
301	Receptor-mediated prednisolone pharmacodynamics in rats: Model verification using a dose-sparing regimen. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 1990, 18, 189-208.	0.6	15
302	Mean residence times of multicompartmental drugs undergoing reversible metabolism. <i>Pharmaceutical Research</i> , 1990, 07, 103-107.	1.7	21
303	Effects of variation in drug elimination on five methods for assessing zero-order drug absorption rates. <i>Pharmaceutical Research</i> , 1990, 07, 76-79.	1.7	1
304	Constant-rate intravenous infusion methods for estimating steady-state volumes of distribution and mean residence times in the body for drugs undergoing reversible metabolism. <i>Pharmaceutical Research</i> , 1990, 07, 628-632.	1.7	7
305	Mean interconversion times and distribution rate parameters for drugs undergoing reversible metabolism. <i>Pharmaceutical Research</i> , 1990, 07, 1003-1010.	1.7	14
306	Steroid dose sparing: Pharmacodynamic responses to single versus divided doses of methylprednisolone in man. <i>Journal of Allergy and Clinical Immunology</i> , 1990, 85, 1058-1066.	1.5	32

#	ARTICLE	IF	CITATIONS
307	Corticosteroid Pharmacodynamics: Models for a Broad Array of Receptor-Mediated Pharmacologic Effects. <i>Journal of Clinical Pharmacology</i> , 1990, 30, 303-310.	1.0	25
308	Second generation model for prednisolone pharmacodynamics in the rat. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 1989, 17, 209-227.	0.6	40
309	Application of mean residence-time concepts to pharmacokinetic systems with noninstantaneous input and nonlinear elimination. <i>Pharmaceutical Research</i> , 1989, 06, 4-12.	1.7	11
310	The area function method for assessing the drug absorption rate in linear systems with zero-order input. <i>Pharmaceutical Research</i> , 1989, 06, 133-139.	1.7	6
311	Effects of obesity and ancillary variables (dialysis time, drug, albumin, and fatty acid concentrations) on theophylline serum protein binding. <i>Biopharmaceutics and Drug Disposition</i> , 1989, 10, 549-562.	1.1	15
312	Pharmacokinetics and pharmacodynamic modeling of direct suppression effects of methylprednisolone on serum cortisol and blood histamine in human subjects. <i>Clinical Pharmacology and Therapeutics</i> , 1989, 46, 616-628.	2.3	73
313	Relationships between steady-state and single-dose plasma drug concentrations for pharmacokinetic systems with nonlinear elimination. <i>Biopharmaceutics and Drug Disposition</i> , 1989, 10, 513-528.	1.1	1
314	Theophylline disposition in foundry workers exposed to coke oven effluent. <i>Biopharmaceutics and Drug Disposition</i> , 1988, 9, 405-409.	1.1	2
315	Analysis of methylprednisolone, methylprednisone and corticosterone for assessment of methylprednisolone disposition in the rat. <i>Biomedical Applications</i> , 1988, 430, 241-248.	1.7	48
316	Pharmacokinetics of single and multiple doses of ethinyl estradiol and levonorgestrel in relation to smoking. <i>Clinical Pharmacology and Therapeutics</i> , 1988, 43, 23-31.	2.3	33
317	Mean residence time concepts for pharmacokinetic systems with nonlinear drug elimination described by the Michaelis-Menten equation. <i>Pharmaceutical Research</i> , 1988, 05, 156-164.	1.7	47
318	Theophylline tissue partitioning and volume of distribution in normal and dietary-induced obese rats. <i>Biopharmaceutics and Drug Disposition</i> , 1987, 8, 353-364.	1.1	17
319	Ketoconazole effects on methylprednisolone disposition and their joint suppression of endogenous cortisol. <i>Clinical Pharmacology and Therapeutics</i> , 1987, 42, 465-470.	2.3	41
320	Application of moment analysis to nonlinear drug disposition described by the Michaelis-Menten equation. <i>Pharmaceutical Research</i> , 1987, 04, 59-61.	1.7	18
321	6β -Methylprednisolone and 6α -Methylprednisone Plasma Protein Binding in Humans and Rabbits. <i>Journal of Pharmaceutical Sciences</i> , 1986, 75, 760-763.	1.6	34
322	Effects of ketoconazole on methylprednisolone pharmacokinetics and cortisol secretion. <i>Clinical Pharmacology and Therapeutics</i> , 1986, 39, 654-659.	2.3	85
323	Pharmacokinetic modeling of bidirectional transfer during peritoneal dialysis. <i>Clinical Pharmacology and Therapeutics</i> , 1986, 40, 209-218.	2.3	30
324	Dose-dependent pharmacokinetics of prednisolone in normal and adrenalectomized rats. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 1986, 14, 453-467.	0.6	35

#	ARTICLE	IF	CITATIONS
325	Receptor-mediated pharmacodynamics of prednisolone in the rat. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 1986, 14, 469-493.	0.6	67
326	The determination of essential clearance, volume, and residence time parameters of recirculating metabolic systems: The reversible metabolism of methylprednisolone and methylprednisone in rabbits. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 1986, 14, 557-599.	0.6	58
327	Moxalactam epimer disposition in patients undergoing continuous ambulatory peritoneal dialysis. <i>Clinical Pharmacology and Therapeutics</i> , 1985, 38, 150-156.	2.3	16
328	Prednisolone disposition in obese men. <i>Clinical Pharmacology and Therapeutics</i> , 1984, 36, 824-831.	2.3	50
329	Theophylline disposition in residents living near a chemical waste site. <i>Biopharmaceutics and Drug Disposition</i> , 1984, 5, 345-355.	1.1	3
330	Determination and Prediction of Tissue Binding of Prednisolone in the Rabbit. <i>Journal of Pharmaceutical Sciences</i> , 1984, 73, 362-366.	1.6	12
331	Fluid Shifts and Other Factors Affecting Plasma Protein Binding of Prednisolone by Equilibrium Dialysis. <i>Journal of Pharmaceutical Sciences</i> , 1984, 73, 774-780.	1.6	133
332	Plasma protein binding interaction of prednisone and prednisolone. <i>The Journal of Steroid Biochemistry</i> , 1984, 21, 337-339.	1.3	23
333	Drug and metabolite concentrations combined in predicting steady-state concentrations from test doses. <i>Biopharmaceutics and Drug Disposition</i> , 1983, 4, 19-29.	1.1	2
334	Binding of prednisolone to α_1 -acid glycoprotein. <i>The Journal of Steroid Biochemistry</i> , 1983, 18, 191-194.	1.3	18
335	Dose- and time-related effect of troleandomycin on methylprednisolone elimination. <i>Clinical Pharmacology and Therapeutics</i> , 1982, 32, 166-171.	2.3	58
336	Prednisolone binding to albumin and transcortin in the presence of cortisol. <i>Biochemical Pharmacology</i> , 1982, 31, 289-292.	2.0	50
337	Distribution Volume Related to Body Weight and Protein Binding. <i>Journal of Pharmaceutical Sciences</i> , 1982, 71, 469-470.	1.6	17
338	Active metabolites of imipramine and desipramine in man. <i>Clinical Pharmacology and Therapeutics</i> , 1982, 31, 393-401.	2.3	90
339	Dose-Dependent Protein Binding and Disposition of Prednisolone in Rabbits. <i>Journal of Pharmaceutical Sciences</i> , 1981, 70, 1201-1204.	1.6	17
340	Analysis of prednisone, prednisolone and their 20 β -hydroxylated metabolites by high-performance liquid chromatography. <i>Biomedical Applications</i> , 1981, 224, 221-227.	1.7	34
341	Effect of smoking on prednisone, prednisolone, and dexamethasone pharmacokinetics. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 1981, 9, 1-14.	0.6	44
342	Dose dependent pharmacokinetics of prednisone and prednisolone in man. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 1981, 9, 389-417.	0.6	160

#	ARTICLE	IF	CITATIONS
343	Monitoring Prednisone and Prednisolone. <i>Therapeutic Drug Monitoring</i> , 1980, 2, 169-176.	1.0	66
344	Serum protein binding of prednisolone in four species. <i>Journal of Pharmaceutical Sciences</i> , 1980, 69, 977-978.	1.6	43
345	Dose-dependent disposition of oral propranolol in normal subjects. <i>Biopharmaceutics and Drug Disposition</i> , 1980, 1, 159-166.	1.1	19
346	Bioavailability of hydrocortisone retention enemas in relation to absorption kinetics. <i>Clinical Pharmacology and Therapeutics</i> , 1980, 28, 262-269.	2.3	11
347	Metabolism and kinetics of oxaprozin in normal subjects. <i>Clinical Pharmacology and Therapeutics</i> , 1980, 27, 352-362.	2.3	46
348	Influence of Cigarette Smoking on Drug Metabolism in Man. <i>Drug Metabolism Reviews</i> , 1979, 9, 221-236.	1.5	121
349	Corticosteroid analysis in biological fluids by high-performance liquid chromatography. <i>Biomedical Applications</i> , 1979, 162, 273-280.	1.7	155
350	Role of tobacco smoking in pharmacokinetics. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 1978, 6, 7-39.	0.6	138
351	Determination of procainamide acetylator status. <i>Clinical Pharmacology and Therapeutics</i> , 1978, 23, 25-29.	2.3	27
352	Theophylline disposition in obesity. <i>Clinical Pharmacology and Therapeutics</i> , 1978, 23, 438-444.	2.3	108
353	Enhanced biotransformation of theophylline in marijuana and tobacco smokers. <i>Clinical Pharmacology and Therapeutics</i> , 1978, 24, 406-410.	2.3	145
354	Pharmacokinetics of Methicillin in Patients with Cystic Fibrosis. <i>Journal of Infectious Diseases</i> , 1977, 135, 828-831.	1.9	100
355	Renal clearance and tissue accumulation of gentamicin. <i>Clinical Pharmacology and Therapeutics</i> , 1977, 22, 364-370.	2.3	121
356	Plasma and Tissue Protein Binding of Drugs in Pharmacokinetics. <i>Drug Metabolism Reviews</i> , 1976, 5, 43-140.	1.5	384
357	Effect of smoking on theophylline disposition. <i>Clinical Pharmacology and Therapeutics</i> , 1976, 19, 546-551.	2.3	212
358	Nonlinear assessment of phenytoin bioavailability. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 1976, 4, 327-336.	0.6	89
359	Digoxin pharmacokinetics: Role of renal failure in dosage regimen design. <i>Clinical Pharmacology and Therapeutics</i> , 1975, 18, 9-21.	2.3	117
360	Pharmacokinetics of ampicillin in cirrhosis. <i>Clinical Pharmacology and Therapeutics</i> , 1975, 18, 475-484.	2.3	54

#	ARTICLE	IF	CITATIONS
361	Pharmacokinetic Design of Digoxin Dosage Regimens in Relation to Renal Function. Journal of Clinical Pharmacology, 1974, 14, 525-535.	1.0	67
362	Myocardial distribution of digoxin and renal function. Clinical Pharmacology and Therapeutics, 1974, 16, 449-454.	2.3	75
363	A pharmacodynamic model for cell-cycle-specific chemotherapeutic agents. Journal of Pharmacokinetics and Pharmacodynamics, 1973, 1, 175-200.	0.6	83
364	Ampicillin and hetacillin pharmacokinetics in normal and anephric subjects. Clinical Pharmacology and Therapeutics, 1973, 14, 90-99.	2.3	59
365	Effects of Change in Elimination on Various Parameters of the Two-Compartment Open Model. Journal of Pharmaceutical Sciences, 1972, 61, 1270-1273.	1.6	90
366	Pharmacodynamics of Chemotherapeutic Effects: Dose-Time-Response Relationships for Phase-Nonspecific Agents. Journal of Pharmaceutical Sciences, 1971, 60, 892-895.	1.6	153
367	Effect of Age on Intestinal Absorption of Riboflavin in Humans. Journal of Pharmaceutical Sciences, 1970, 59, 487-490.	1.6	18
368	Pharmacokinetic Evidence for Saturable Renal Tubular Reabsorption of Riboflavin. Journal of Pharmaceutical Sciences, 1970, 59, 765-772.	1.6	53
369	Multicompartment Pharmacokinetic Models and Pharmacologic Effects. Journal of Pharmaceutical Sciences, 1969, 58, 422-424.	1.6	61
370	Factors Affecting the Absorption of Riboflavin in Man. Journal of Pharmaceutical Sciences, 1966, 55, 285-289.	1.6	156
371	Effect of Viscosity on Drug Absorption. Journal of Pharmaceutical Sciences, 1965, 54, 219-225.	1.6	76
372	Pharmacogenomics and Pharmacokinetic/Pharmacodynamic Modeling. , 0, , 509-528.		1
373	Mechanistic Pharmacokinetic/Pharmacodynamic Models II. , 0, , 607-631.		3